Age-related macular degeneration market will rise to $11.5 billion by 2026
Pharmaceutical sales for age-related macular degeneration (AMD) marketplaces were projected to be $4.9 billion in 2016, and it’s expected to reach a price of $11.5 billion in 2026, with a Compound Annual Growth Rate (CAGR) rise of 8.9%, stated by a leading data and analytics company.